Last reviewed · How we verify

Lenalidomide and Dexamethasone — Competitive Intelligence Brief

Lenalidomide and Dexamethasone (Lenalidomide and Dexamethasone) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunomodulatory agent + corticosteroid combination. Area: Oncology.

phase 3 Immunomodulatory agent + corticosteroid combination Cereblon (CRBN), TNF-α pathway; glucocorticoid receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Lenalidomide and Dexamethasone (Lenalidomide and Dexamethasone) — HuniLife Biotechnology, Inc.. Lenalidomide enhances immune cell activity and has anti-angiogenic properties, while dexamethasone provides anti-inflammatory and immunosuppressive effects to manage multiple myeloma.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Lenalidomide and Dexamethasone TARGET Lenalidomide and Dexamethasone HuniLife Biotechnology, Inc. phase 3 Immunomodulatory agent + corticosteroid combination Cereblon (CRBN), TNF-α pathway; glucocorticoid receptor
VRD for first-cycle induction therapy VRD for first-cycle induction therapy The First Affiliated Hospital of Soochow University marketed Proteasome inhibitor + immunomodulatory agent + corticosteroid combination 26S proteasome (bortezomib); cereblon/CRBN (lenalidomide); glucocorticoid receptor (dexamethasone)
Drug: Carfilzomib + Lenalidomide + Dexamethasone Drug: Carfilzomib + Lenalidomide + Dexamethasone Amgen marketed Proteasome inhibitor + Immunomodulatory agent + Corticosteroid combination 20S proteasome (carfilzomib); cereblon/CRBN (lenalidomide); glucocorticoid receptor (dexamethasone)
Lenalidomide/Low dose Dex Lenalidomide/Low dose Dex King Faisal Specialist Hospital & Research Center phase 3 Immunomodulatory agent + corticosteroid combination Cereblon (CRBN), TNF-α pathway, glucocorticoid receptor
Bortezomib/Lenalidomide/ Low dose Dex Bortezomib/Lenalidomide/ Low dose Dex King Faisal Specialist Hospital & Research Center phase 3 Proteasome inhibitor + Immunomodulatory agent + Corticosteroid combination Proteasome (bortezomib); Cereblon (lenalidomide); Glucocorticoid receptor (dexamethasone)
Carfilzomib Lenalidomide Dexamethasone Carfilzomib Lenalidomide Dexamethasone European Myeloma Network B.V. phase 3 Proteasome inhibitor + Immunomodulatory agent + Corticosteroid combination 20S proteasome (carfilzomib); Cereblon/E3 ubiquitin ligase (lenalidomide); Glucocorticoid receptor (dexamethasone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunomodulatory agent + corticosteroid combination class)

  1. HuniLife Biotechnology, Inc. · 1 drug in this class
  2. King Faisal Specialist Hospital & Research Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lenalidomide and Dexamethasone — Competitive Intelligence Brief. https://druglandscape.com/ci/lenalidomide-and-dexamethasone. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: